Showing 4141-4150 of 5911 results for "".
- CooperVision to Spotlight Myopia Control and Management Advocacy at ESCRShttps://modernod.com/news/coopervision-to-spotlight-myopia-control-and-management-advocacy-at-escrs/2481809/CooperVision will spotlight advancing myopia control and management as standard of care across all ocular health sectors at the 2023 European Society of Cataract and Refractive Surgeons (ESCRS) conference in Vienna. On September 7, a thought leadership panel will be held
- Rayner Unveils Enhancements to Digital Platforms at ESCRS 2023https://modernod.com/news/rayner-unveils-enhancements-to-digital-platforms-at-escrs-2023/2481808/Rayner has announced a series of updates to its digital platforms, RayPRO and Peer2Peer, designed to redefine patient-reported outcome measures (PROMs) and elevate clinical ophthalmic education. Attendees of the ESCRS 2023 congress are invited to explore these advancements at Booth B303
- EyeSouth Partners Affiliates with Retina and Vitreous of Texashttps://modernod.com/news/eyesouth-partners-affiliates-with-retina-and-vitreous-of-texas/2481807/EyeSouth Partners has announced that it has partnered with Retina and Vitreous of Texas (RVT), in Houston. The affiliation represents EyeSouth’s 38th overall and the network’s first retina-only affiliation in the state of Texas. Financial terms of the deal were not disclosed
- OcuCell Secures Funding from The Eye-Bank for Sight Restorationhttps://modernod.com/news/ocucell-secures-funding-from-the-eye-bank-for-sight-restoration/2481804/Ocular cell therapy company OcuCell announced it has received seed funding from The Eye-Bank for Sight Restoration (EBSR). The funding will enable OcuCell to accelerate its mission of transforming the corneal cell therapy landscape through the development of cell therapy solut
- Sydnexis Appoints Nick Ruth Chief as Commercial Officerhttps://modernod.com/news/sydnexis-appoints-nick-ruth-chief-as-commercial-officer/2481799/Sydnexis has announced the appointment of industry veteran Nick Ruth, MBA, as its Chief Commercial Officer (COO). Mr. Ruth will lead Sydnexis’ commercial strategy and transition from a clinical based organization to both a clinical and commercial based organization. With
- Zeiss Surpasses 8 Million Eyes Treated with SMILE Worldwidehttps://modernod.com/news/zeiss-surpasses-8-million-eyes-treated-with-smile-worldwide/2481789/Zeiss announced that more than 8 million eyes have been treated with Small Incision Lenticule Extraction (SMILE) globally to date. The FDA approved the VisuMax Femtosecond Laser for the SMILE procedure in 2016. “Zeiss SMILE is a game-changer for lase
- ScienceBased Health Welcomes New Members to Its Optometry Clinical Advisory Panelhttps://modernod.com/news/sciencebased-health-welcomes-new-members-to-its-optometry-clinical-advisory-panel/2481787/ScienceBased Health (SBH) announced the addition of Jaclyn Garlich, OD, FAAO; Jacob Lang, OD, FAAO, Dipl ABO; and Mark Schaeffer, OD to its Optometry Clinical Advisory Panel. ScienceBased Health develops and markets e
- Neurophth Announces First Patient Dosed in Phase 1/2 Clinical Trial of Second Gene Therapyhttps://modernod.com/news/neurophth-announces-first-patient-dosed-in-phase-12-clinical-trial-of-second-gene-therapy/2481786/Neurophth Therapeutics announced that the first patient has been dosed in the international multi-region, multicenter phase 1/2 clinical trial for the treatment of Leber hereditary optic neuropathy caused by ND1 mutation (ND1-LHON). Neurophth is conducting a phase 1/2, mu
- Amber Ophthalmics Announces First Patient Enrolled in Phase 2/3 Trial Evaluating Nexagon for the Treatment of PCEDhttps://modernod.com/news/amber-ophthalmics-announces-first-patient-enrolled-in-phase-23-trial-evaluating-nexagon-for-the-treatment-of-pced/2481785/Amber Ophthalmics announced that Mark S. Gorovoy, MD, has enrolled the first patient in the AMB-01-006 (NEXPEDE-1), a randomized, double-masked, vehicle-controlled phase 2/3 clinical trial designed to evaluate two concentrations of Nexagon (lufepirsen ophthalmic gel) for
- ViGeneron Announces EMA Approval of Clinical Trial Application for VG901, a Gene Therapy to Treat RPhttps://modernod.com/news/vigeneron-announces-ema-approval-of-clinical-trial-application-for-vg901-a-gene-therapy-to-treat-retinitis-pigmentosa/2481784/ViGeneron announced that the European Medicines Agency (EMA) has approved the clinical trial application for VG901, a gene therapy to treat CNGA1-associated retinitis pigmentosa (RP). VG901 uses vgAAV, ViGeneron's proprietary adeno-associated virus (AAV) vector to deliver the CNGA1